Objectives: To evaluate the activity of the orally bioavailable enfumafungin derivative MK-3118 and comparator antifungal agents tested against a collection of 113 clinical isolates of Candida spp. using CLSI and EUCAST broth microdilution (BMD) methods.
Introduction
The echinocandins, anidulafungin, caspofungin and micafungin, are now well-established as first-line agents for the treatment of invasive candidiasis (IC) and serve as the prime example for the efficacy of inhibitors of glucan synthase (GS) as antifungal agents. 1 Despite this clinical success, one important limitation of the echinocandins is the requirement for intravenous administration. An orally bioavailable GS inhibitor with comparable antifungal activity to the echinocandins would provide a valuable benefit for the treatment and prophylaxis of IC and other fungal infections. 2 Derivatives of the natural product enfumafungin are potent inhibitors of GS yet are structurally distinct from the echinocandins. 2 -4 MK-3118 is a semi-synthetic orally bioavailable derivative of enfumafungin with in vitro and in vivo activity against several different species of Candida and Aspergillus. 2,5 -9 Notably, MK-3118 has been shown to retain in vitro activity against both azole-and echinocandin-resistant strains of Candida. 2, 7 Mutations in fks that result in resistance to the echinocandins are located in domains other than those associated with decreased susceptibility to MK-3118 and related compounds, supporting the lack of cross-resistance between these agents that has been demonstrated in vitro. 7 Preliminary data using the CLSI broth microdilution (BMD) method 10 has demonstrated the excellent potency and spectrum of MK-3118 against Candida spp.; 7 however, specific methodological parameters such as the duration of incubation, MIC endpoint criteria (EC) and the level of agreement between the CLSI and EUCAST BMD methods must be investigated. 10 -12 The similarities and differences between the CLSI and EUCAST international standards for BMD testing of Candida spp. have been outlined in several previous publications.
13 -17 Whereas we have shown previously that the two reference methods provide concordant results when testing both triazoles and echinocandins against Candida spp., 15, 16, 18 similar data are not available for MK-3118. Given the important role that both methods play in antifungal development and resistance surveillance, it is important to demonstrate the comparability of the results in the pre-clinical studies of new antifungal agents.
In the present study, we determined the activity and potency of MK-3118, caspofungin and fluconazole against a panel of Candida spp. isolates selected to represent phenotypically and genotypically antifungal-resistant strains. We first examined the effect of incubation time and MIC EC on the results of the CLSI method and subsequently determined the essential agreement (EA; MIC +2 log 2 dilutions) between CLSI and EUCAST BMD results using the optimized CLSI conditions. 19 Prior to testing, each isolate was passaged at least twice onto Sabouraud dextrose agar (Remel, Lenexa, KS, USA) and CHROMagar Candida medium (Becton Dickinson, Sparks, MD, USA) to ensure purity and viability.
Materials and methods
All isolates were tested for in vitro susceptibility to MK-3118 using the CLSI and EUCAST BMD methods. 10 -12 The reference powder of MK-3118 was obtained from the manufacturer. Stock solutions were prepared in DMSO and the final range of MK-3118 concentrations tested was 0.008-16 mg/L. CLSI BMD testing was performed exactly as outlined in documents M27-S3 and M27-A3 10, 20 by using RPMI 1640 medium with 0.2% glucose, inocula of 0.5×10 3 to 2.5×10 3 cells/mL and incubation at 358C. MIC values were determined visually after both 24 and 48 h of incubation. MIC EC at both reading times include the lowest concentration of drug that caused a significant diminution (≥50% inhibition) as well as complete (100%) inhibition of growth relative to that of the growth control. CLSI clinical breakpoints for each antifungal agent and species are as follows: fluconazole and C. albicans, C. tropicalis and C. parapsilosis . MIC values were determined spectrophotometrically (at 530 nm) after 24 h of incubation, as the lowest concentration of drug that resulted in both ≥50% inhibition and 100% inhibition of growth relative to that of the growth control. Quality control was ensured by testing the following strains recommended by CLSI 10 and EUCAST: 11,12 C. krusei ATCC 6258 and C. parapsilosis ATCC 22019.
The MIC results for MK-3118 obtained with the CLSI method using both partial (≥50%) and complete (100%) inhibition were compared at each reading time in order to determine the EA between MIC values obtained at 24 and 48 h with each EC and subsequently to determine the EA at 24 h between MIC values determined using partial versus complete EC. The MIC results for MK-3118 obtained with the EUCAST method were compared with those of the CLSI method at 24 h of incubation using both complete and partial inhibition EC for both methods. High offscale MIC results were converted to the next highest concentration and low off-scale MIC results were left unchanged. Discrepancies of .+2 log 2 dilutions among MIC results were used to calculate the EA. Table 1 summarizes the in vitro susceptibilities of 113 isolates of Candida spp. to MK-3118 determined by the CLSI BMD method. The MIC results determined by the CLSI method ranged from 0.06 to 16 mg/L depending upon the species, duration of incubation and MIC EC. Overall, the EA between the 24 and 48 h CLSI readings was 99.1% (95.6% within +1 dilution) using the partial inhibition (≥50%) EC and 98.2% (90.4% within +1 dilution) using the complete (100%) inhibition EC. Given that the 24 and 48 h MIC readings were comparable, and assuming All results displayed were read at 24 h and 50% inhibition.
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JAC that an earlier MIC reading would be preferable to a later reading, we determined the EA between MIC results read at 24 h of incubation using the two different ECs. Comparison of the partial and complete inhibition MIC results obtained with the CLSI method at 24 h of incubation showed an overall EA of 97.1% (85.7% within +1 dilution).
Comparison of CLSI and EUCAST methods read at 24 h of incubation and either partial or complete inhibition revealed an EA of 99.1% (88.5% within +1 dilution; Table 2 ) using the partial inhibition EC and 93.2% (87.6% within +1 dilution) using the complete inhibition EC (Table 2) . Thus, the testing conditions for MK-3118 that optimize the agreement between the CLSI and EUCAST methods appear to be incubation for 24 h and a partial inhibition EC (50% inhibition relative to control). Among the few discrepancies noted, the CLSI method tended to produce higher values with C. albicans, whereas the EUCAST method usually gave higher values with C. tropicalis. Table 3 displays the in vitro activity of MK-3118 and the two antifungal comparator agents tested against the five major species of Candida using CLSI and EUCAST methods (results read at 50% inhibition and 24 h of incubation). MK-3118 was quite active against all species tested (MIC 90 of 0.5-2 mg/L for both methods), including C. albicans (MIC 90 , 1 and 1 mg/L, respectively, for CLSI and EUCAST methods), C. glabrata (2 and 1 mg/L, respectively), C. parapsilosis (0.5 and 0.5 mg/L, respectively), C. tropicalis (1 and 1 mg/L, respectively) and C. krusei (2 and 1 mg/L, respectively). This compound displayed similar activity to caspofungin against C. albicans, C. parapsilosis, C. tropicalis and C. krusei, and was 8-fold more potent than caspofungin against C. glabrata strains (MIC 90 , 2 and 16 mg/L, respectively) when tested by the CLSI method. The challenging nature of this organism collection is evident from the high levels of resistance to fluconazole (19.1% -44.8%) and caspofungin (0.0% -34.5%; Table 3 ) among the strains selected for testing.
MK-3118 was also active against 31 strains shown to have mutations in the hot spots (HS) of fks1 or fks2 (Table 4) , inhibiting all these strains at ≤2 mg/L and 22 (71.0%) strains at ≤1 mg/L using the CLSI method. Among the nine isolates showing MK-3118 MIC values of 2 mg/L (CLSI BMD), three were C. albicans, three were C. glabrata, two were C. tropicalis and one was C. krusei; seven (77.8%) of these strains had mutations in position 641 (or 625 for C. glabrata and 655 for C. krusei numbering schemes) of the fks1 HS1. The caspofungin MIC results were elevated [either intermediate or resistant (CLSI BMD)] for 27 (87.1%) of the 31 fks mutants: three isolates of C. glabrata and one of C. tropicalis appeared susceptible to caspofungin with MIC results of 0.12 and 0.25 mg/L (CLSI BMD), respectively, despite having mutations in either fks1 or fks2 (Table 4) .
MK-3118 was also active against fluconazole-resistant strains of C. albicans [MIC range, 0.06-2 mg/L; Table 5 (CLSI BMD) Table 5 ) strains. It is notable that 14 of the 34 fluconazole-resistant strains included in this study were also resistant to caspofungin: 8 of 13 C. albicans (61.5%) and 6 of 12 C. glabrata (50.0%) ( Table 5) .
The results of this pre-clinical method assessment of the in vitro activity of MK-3118 against Candida spp. indicate that the drug may be tested using either the CLSI or EUCAST BMD method and an incubation time of only 24 h. Although partial or complete inhibition MIC endpoints give comparable results, the highest levels of inter-and intra-method agreement was observed when the partial inhibition (≥50%) EC was used for both methods, and this selection would produce reference results earlier.
In summary, MK-3118 was identified as a potent new inhibitor of GS with impressive in vitro activity against both azole-and echinocandin-resistant strains of Candida, as shown by both international reference methods. Optimal testing conditions using CLSI and EUCAST methods include 24 h of incubation and an inhibition MIC EC of ≥50%. Further development of this new antifungal agent appears warranted. Pfaller et al.
